RxDoctor Payments Data

Alyssa Keller, MD

Family Medicine · O Fallon, MONPI 1588892665

Payments from drug & device makers

$4,795in general payments, 2019–2025

Across 265 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$630
  • Novo Nordisk$478
  • AstraZeneca$474
  • Boehringer Ingelheim$303
  • Pfizer$276
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$4,788100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,795 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$35,078
Medicare patients
102
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide32$45,133
OzempicSemaglutide32$44,955
FarxigaDapagliflozin Propanediol20$22,022
JanuviaSitagliptin Phosphate19$12,664
ArexvyRsvpref3 Antigen/As01e/Pf31$8,023
Atorvastatin Calcium337$2,308
Omeprazole139$2,208
Lisinopril224$1,249
Levothyroxine Sodium154$1,209
Fluticasone Propionate53$1,181
Losartan Potassium195$1,142
Rosuvastatin Calcium145$1,085
Metoprolol Succinate81$1,071
Esomeprazole Magnesium32$986
Glipizide ErGlipizide52$936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$630$45,13332 claims
Novo NordiskOzempic$478$44,95532 claims
AstraZenecaFarxiga$474$22,02220 claims
MerckJanuvia$23$12,66419 claims
GSKArexvy$206$8,02331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in O Fallon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →